Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

Research analysts at began coverage on shares of Evoke Pharma (NASDAQ:EVOKGet Free Report) in a research report issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of EVOK opened at $0.50 on Wednesday. Evoke Pharma has a 1-year low of $0.40 and a 1-year high of $1.96. The company has a market capitalization of $4.30 million, a P/E ratio of -0.27 and a beta of 0.36. The firm’s 50 day simple moving average is $0.49 and its 200 day simple moving average is $0.74.

Evoke Pharma (NASDAQ:EVOKGet Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The company had revenue of $1.74 million for the quarter.

Evoke Pharma Company Profile

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Recommended Stories

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.